The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.
Not Applicable
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000018758
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
Patient considered irrelevant by attending physician for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical outcome(Survival, relapse) Biomarkers
- Secondary Outcome Measures
Name Time Method